Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
NCT06435260
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
Camrelizumab+chemotherapy
RADIATION:
hypofractionated radiotherapy
Sponsor
Hebei Medical University Fourth Hospital